The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.
- First select the CSR Section, then a Table/Figure from that section.
- Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.
To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 158 KB) and Technical Notes (PDF, 452 KB) pages.
Download and Print: Download Printer-friendly PDF Download data
Table 4.27
Cancer of the Female Breast(In Situ)
| Histologya | All Races | White | Black | Asian/ Pacific Islander |
American Indian /Alaska Nativeb |
Hispanicc | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Count | Percent | Count | Percent | Count | Percent | Count | Percent | Count | Percent | Count | Percent | |
| Adenocarcinomad | 69,788 | 99.7% | 55,680 | 99.7% | 6,974 | 99.6% | 6,009 | 99.8% | 185 | 100.0% | 6,075 | 99.8% |
| Adenocarcinoma in situ, NOS (8140/2) | - | - | - | - | - | - | - | - | - | - | - | - |
| Ductal carcinoma in situe | 58,818 | 84.0% | 46,439 | 83.2% | 6,074 | 86.8% | 5,471 | 90.9% | 154 | 83.2% | 5,172 | 85.0% |
| Cribiform carcinoma in situ (8201/2) | 5,743 | 8.2% | 4,477 | 8.0% | 578 | 8.3% | 587 | 9.8% | 23 | 12.4% | 551 | 9.1% |
| Ductal carcinoma in situ, solid type(8230/2) | 4,094 | 5.8% | 3,369 | 6.0% | 323 | 4.6% | 350 | 5.8% | - | - | 329 | 5.4% |
| Ductal carcinoma in situ, NOS (8500/2) | 23,106 | 33.0% | 18,534 | 33.2% | 2,403 | 34.3% | 1,839 | 30.6% | 59 | 31.9% | 1,904 | 31.3% |
| Comedocarcinoma in situ (8501/2) | 5,142 | 7.3% | 4,108 | 7.4% | 537 | 7.7% | 429 | 7.1% | - | - | 471 | 7.7% |
| Ductal carcinoma in situ papillary(8503/2) | 1,142 | 1.6% | 799 | 1.4% | 191 | 2.7% | 122 | 2.0% | - | - | 110 | 1.8% |
| Noninfiltrating intracystic carcinoma(8504/2) | 323 | 0.5% | 213 | 0.4% | 48 | 0.7% | 56 | 0.9% | - | - | 28 | 0.5% |
| Ductal carcinoma in situ micropapillary(8507/2) | 1,629 | 2.3% | 1,300 | 2.3% | 190 | 2.7% | 113 | 1.9% | - | - | 140 | 2.3% |
| Intraductal with other types of carcinoma in situ(8523/2) | 17,444 | 24.9% | 13,482 | 24.1% | 1,788 | 25.5% | 1,955 | 32.5% | 30 | 16.2% | 1,617 | 26.6% |
| Lobular carcinoma in situ (8520/2-8521/2, 8524/2) | 7,953 | 11.4% | 6,783 | 12.1% | 597 | 8.5% | 329 | 5.5% | 20 | 10.8% | 649 | 10.7% |
| Lobular carcinoma in situ, NOS (8520/2) | 7,927 | 11.3% | 6,760 | 12.1% | 594 | 8.5% | 329 | 5.5% | 20 | 10.8% | 649 | 10.7% |
| Lobular CISf with other CISf (8524/2) | 25 | 0.0% | 23 | 0.0% | - | - | - | - | - | - | - | - |
| Intraductal and lobular in situ carcinoma (8522/2) | 2,500 | 3.6% | 2,068 | 3.7% | 234 | 3.3% | 160 | 2.7% | - | - | 218 | 3.6% |
| Other adenocarcinomasg | 505 | 0.7% | 379 | 0.7% | 69 | 1.0% | 48 | 0.8% | - | - | 36 | 0.6% |
| Other in situ histologiesh | 209 | 0.3% | 167 | 0.3% | 27 | 0.4% | - | - | - | - | - | - |
| Total | 69,997 | 100.0% | 55,847 | 100.0% | 7,001 | 100.0% | 6,019 | 100.0% | 185 | 100.0% | 6,088 | 100.0% |
Footnotes:
Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Percents may not sum to 100 due to rounding.
a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.
b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.
c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.
d Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.
e Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.
f CIS = Carcinoma in situ.
g Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.
h Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.
- Statistic not shown due to fewer than 16 cases during the time period.
Page Navigation: << Previous Next >>
The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.